Novo Nordisk says new data shows degludec superior | Reuters
Links shared publicly online about this topic.
- 315total visits
Novo Nordisk says new data shows degludec superior | Reuters
* New data shows degludec superior to Lantus * Sanofi gaining, Eli Lilly losing market share * Has begun phase IIIa clinical trial of haemophilia compound COPENHAGEN, May 5 (Reuters) - Danish
View full resource at reuters.com
Tags: Diabetes Type 1 Medication, Diabetes Type 2 Medication, Diabetes Medication, Insulin, Lantus, Sanofi-Aventis, Eli Lilly and Company, Novo Nordisk
Most Recently Shared on May 5, 2011 at 11:03 am By:
Novo claims IIIa data demonstrates Degludec (once daily insulin) bests Sanofi's Lantus (once daily insulin). http://reut.rs/kgkvbb
Advertisement
